ABT-299

• Description:

  ABT-299 is a prodrug of a platelet-activating factor (PAF) antagonist that exhibits significant inhibitory activity on PAF-induced β-platelet globulin release in vitro after in vivo administration in humans, an effect that may be partially attributed to the pyridine-N-oxide metabolite.

• UNSPSC:

  12352005

• Target:

  Platelet-activating Factor Receptor (PAFR)

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/abt-299.html

• Smiles:

  CC (OC[N+]1=CC=CC ([C@H]2SCC3=C (C=CN23) C (C4=CN (C5=C4C=CC (C6=CC=C (C=C6) F) =C5) C (N (C) C) =O) =O) =C1) =O.[Cl-]

• Molecular Formula:

  C32H28ClFN4O4S

• Molecular Weight:

  619.11

• References & Citations:

  [1]Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist|[2]Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  161395-35-3